Drugs to cure avian influenza infection multiple ways to prevent cell death

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Yuan, S ^a  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Acute respiratory distress syndrome; Avian influenza virus infection; Cell death; Combination therapy; Reactive oxygen species

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ASCORBIC ACID; CELECOXIB; CYANOVIRIN N; CYCLOSPORIN A; DAS 181; ERITORAN; FAVIPIRAVIR; GELDANAMYCIN; LANINAMIVIR OCTANOATE; MESALAZINE; OSELTAMIVIR; PERAMIVIR; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RIMANTADINE; SIALIDASE; SIVELESTAT; ULINASTATIN; UNCLASSIFIED DRUG; ZANAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL ACTIVITY; ARTIFICIAL VENTILATION; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CELL DEATH; CELL MEMBRANE PERMEABILITY; COMMON COLD; DRUG EFFICACY; ENCEPHALITIS; HEPATITIS; HUMAN; HYPOXIC LUNG VASOCONSTRICTION; IMMUNE RESPONSE; INFLAMMATION; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LYSOSOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRION SWELLING; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTICEMIA; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; CELL DEATH; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS;

EID: 84887452181     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.367     Document Type: Review

References (72)

1. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan J-H et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368: 2277-2285
2. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-1897
3. World Health Organization (WHO). Update 49-SARS case fatality ratio, incubation period 2003. http://www.who.int/csr/sars/archive/2003-05-07a/en/.
4. World Health Organization (WHO). Epidemiology of WHO-confirmed human cases of avian A (H5N1) infection, 30 June 2006. Weekly Epidemiol Record 2006; 81: 249-260
5. World Health Organization (WHO)The A/ 2009 H1N1 influenza virus pandemic 2009. http://www.who.int/vaccine-research/diseases/ari/en/index5.html
6. Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6: 135
7. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008; 4: E1000115
8. Cilloniz C, Pantin-Jackwood MJ, Ni C, Goodman AG, Peng X, Projl SC et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol 2010; 84: 7613-7624
9. Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: The contributions of virus and host factors. Curr Opin Immunol 2011; 23: 481-486
10. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: Clinical analysis and characterisation of viral genome. Lancet 2013; 381: 1916-1925
11. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499: 500-503
12. Tasaka S, Amaya F, Hashimoto S, Ishizaka A. Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. Antioxid Redox Signal 2008; 10: 739-753
13. Bland JS. Vitamin C: The Future is Now (Keats Good Health Guide). McGraw-Hill Press: Columbus, Ohio, USA, 1998. pp 1-48
14. Pauling L. Vitamin C And The Common Cold. Freeman Press: San Francisco, California, USA, 1970
15. Thorson A, Petzold M, Nguyen TK, Ekdahl K. Is exposure to sick or dead poultry associated with flulike illness?: A population-based study from a rural area in Vietnam with outbreaks of highly pathogenic avian influenza. Arch Intern Med 2006; 166: 119-123
16. Ely JT. Ascorbic acid role in containment of the world avian flu pandemic. Exp Biol Med 2007; 232: 847-851
17. Lewin S. Vitamin C: Its Molecular Biology and Medical Potential. Academic Press: New York, New Jersey, USA, 1976
18. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662
19. Zhang ZW, Cheng J, Xu F, Yuan M, Du JB, Shang J et al. Mammal cells double their total RNAs against diabetes, ischemia reperfusion and malaria-induced oxidative stress. Mol Med 2011; 17: 533-541
20. Zhang ZW, Cheng J, Xu F, Chen YE, Du JB, Yuan M et al. Red blood cell extrudes nucleus and mitochondria against oxidative stress. IUBMB Life 2011; 63: 560-565
21. Yamada Y, Limmon GV, Zheng D, Li N, Li L, Yin L et al. Major shifts in the spatio-temporal distribution of lung antioxidant enzymes during influenza pneumonia. PLoS One 2012; 7: E31494
22. Ueda M, Daidoji T, Du A, Yang CS, Ibrahim MS, Ikuta K et al. Highly pathogenic H5N1 avian influenza virus induces extracellular Ca2+ influx, leading to apoptosis in avian cells. J Virol 2010; 84: 3068-3078
23. Fuchs B, Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Grimminger F et al. Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2010; 174: 282-291
24. Creagh-Brown BC, Griffiths MJD, Evans TW. Bench-to-bedside review: Inhaled nitric oxide therapy in adults. Crit Care 2009; 13: 221
25. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: A mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831-1837
26. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-8096
27. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: Implications for treatment strategies. J Infect Dis 2010; 201: 346-353
28. Han D, Ybanez MD, Ahmadi S, Yeh K, Kaplowitz N. Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal 2009; 11: 2245-2263
29. Low IC, Kang J, Pervaiz S. Bcl-2: A prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 2011; 15: 2975-2987
30. Sun Y, Li C, Shu Y, Ju X, Zou Z, Wang H et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. Sci Signal 2012; 5: Ra16
31. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815
32. Frantz B, Nordby EC, Bren G, Steffan N, Paya CV, Kincaid RL et al. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J 1994; 13: 861-870
33. Grigoriu S, Bond R, Cossio P, Chen JA, Ly N, Hummer G et al. The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol 2013; 11: E1001492
34. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008; 14: 442-447
35. Guo HX, Wang F, Yu KQ, Chen J, Bai DL, Chen KX et al. Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca2+ uptake/ release. Acta Pharmacol Sin 2005; 26: 1201-1211
36. Dandel M, Lehmkuhl HB, Knosalla C, Hetzer R. Impact of different long-term maintenance immunosuppressive therapy strategies on patients outcome after heart transplantation. Transpl Immunol 2010; 23: 93-103
37. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, Matsuoka Y et al. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 2009; 83: 5825-5834
38. Liu X, Zhao Z, Li Z, Xu C, Sun L, Chen J et al. Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One 2012; 7: E37277
39. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133: 235-249
40. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497: 498-502
41. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5564) treatment for sepsis: Review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011; 7: 479-494
42. Shimamoto A, Pohlman TH, Shomura S, Tarukawa T, Takao M, Shimpo H. Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg 2006; 82: 2017-2023
43. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 2009; 32: 4-16
44. Iwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): A systematic review and meta-analysis. Intern Med 2010; 49: 2423-2432
45. Ito K, Mizutani A, Kira S, Mori M, Iwasaka H, Noguchi T. Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury 2005; 36: 387-394
46. Yamasaki F, Ishibashi M, Nakakuki M, Watanabe M, Shinkawa T, Mizota M. Protective action of ulinastatin against cisplatin nephrotoxicity in mice and its effect on the lysosomal fragility. Nephron 1996; 74: 158-167
47. Ju XW. The Mechanism of Lysosome Depletion Induced by the Highly Pathogenic Avian Influenza Virus H5N1 Infection. PhD Dissertation of Peking Union Medical College: Beijing, China, 2012
48. White NJ, Webster RG, Govorkova EA, Uyeki TM. What is the optimal therapy for patients with H5N1 influenza? PLoS Med 2009; 6: E1000091
49. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelhelthaler DM et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53: 4115-4126
50. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5: E9332
51. Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 374: 198-209
52. Macdonald SJF, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at once-weekly dosing regimen. Antimicrob Agents Chemother 2004; 48: 4542-4549
53. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49: 981-986
54. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH et al. Efficacy of orally administered T-705 on lethal avian influenza A(H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-851
55. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-1479
56. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196: 1493-1499
57. Smee DF, Bailey KW,Wong MH, OKeefe BR, Gustafson KR, Mishin VP et al. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008; 80: 266-271
58. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284: 29798-29808
59. Kim JH, Resende R, Wennekes T, Chen HM, Bance N, Buchini S et al. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 2013; 340: 71-75
60. Chase G, Deng T, Fodor E, Leung BW, Mayer D, Schwemmle M et al. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 2008; 377: 431-439
61. Liu PP, Hu Y, Zhao BH, Zhong F, He HX. Geldanamycin reduces proliferation of highly pathogenic H5N1 avian influenza virus in vivo. Chin Sci Bull 2013; 58: 1021-1026
62. Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 2009; 48: S3-S13
63. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70: 1349-1362
64. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41: 183-190
65. Demling RH. The modern version of adult respiratory distress syndrome. Annu Rev Med 1995; 46: 193-202
66. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122: 2731-2740
67. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273-2279
68. Koinuma D, Miki M, Ebina M, Tahara M, Hagiwara K, Kondo T et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med 2002; 41: 26-29
69. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994; 18: 516-524
70. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15: 279-290
71. Barbaro D, Orsini P, Pallini S, Piazza F, Pasquini C. Obesity in transplant patients: Case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002; 8: 124-126
72. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: Ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet 2006; 45: 169-175